Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€117.00

€117.00

-0.830%
-1.0
-0.830%
€112.48

€112.48

 
29.07.26 / Tradegate WKN: A2AP32 / Symbol: PTGX / Name: Protagonist / Stock / Micro Cap /
Latest predictions
17.07.26
-5.65%
buy
01.07.26
3.54%
buy
22.05.26
39.29%
buy
€116.17
21.05.26
32.95%
buy
€100.68
06.05.26
39.29%
buy
€95.74
19.03.26
32.95%
buy
Best running prediction
-
07.08.25
168.35%
buy
Your prediction

Protagonist Therapeutics Inc Stock

The price for the Protagonist Therapeutics Inc stock decreased slightly today. Compared to yesterday there is a change of -€1.000 (-0.830%).
With 27 Buy predictions and not a single Sell prediction Protagonist Therapeutics Inc is an absolute favorite of our community.
However, we have a potential of -4.27% for Protagonist Therapeutics Inc as the target price of 112 € is below the current price of 117.0 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Protagonist Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Protagonist Therapeutics Inc in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Protagonist Therapeutics (PTGX) had its "outperform" rating reaffirmed by Citigroup Inc..
Ratings data for PTGX provided by MarketBeat
Show more

Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by TD Cowen.
Ratings data for PTGX provided by MarketBeat
Show more

Protagonist Therapeutics (PTGX) was upgraded by Wolfe Research to "strong-buy".
Ratings data for PTGX provided by MarketBeat
Show more

News

Takeda Pharmaceutical Q1 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
Takeda Pharmaceutical Q1 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit

Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.

According to its

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance

On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of